New mpox data amid an evolving outbreak
We are four years into the global mpox outbreak with continued widespread transmission of the Clade 2b strain, and more recently transmission of Clade 1b mpox outside of sub-Saharan Africa. We have no proven therapeutics for mpox other than supportive care. Most countermeasures used during the outbreak were developed for smallpox and approved without human efficacy data for mpox.1 We are now faced with an ongoing, smouldering outbreak, with low case counts, that makes vaccine and treatment trials challenging to enrol.
Authors
- Jason E Zucker (ORCID: https://orcid.org/0000-0001-6987-6412)
- Timothy J. Wilkin (ORCID: https://orcid.org/0000-0001-9386-9335)
Institutions
- Columbia University Irving Medical Center (US)
- UC San Diego Health System (US)
- University of California San Diego (US)
Publication Details
- Journal
- EBioMedicine
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1016/j.ebiom.2026.106559
- Primary Topic
- Poxvirus research and outbreaks
- Type
- article
- Field-Weighted Citation Impact
- 0.00